The significance of STEP-HFpEF trial is that it demonstrated benefits of semaglutide in nondiabetic patients with HFpEF and obesity
95% CI, 0.65-0.76)
However, slowing the digestive process can disrupt the normal movement of stool through your intestines, leading to either constipation or loose stools depending on your individual gut biology
MACEs, major adverse cardiac events
Orforglipron (Foundayo) is a daily tablet that works on the GLP-1 pathway to reduce appetite, while Mounjaro is a weekly injection that targets both GLP-1 and GIP, making it more potent
With this device, we track our patients weight, percent body fat, muscle mass, metabolism, hydration status, visceral fat, and more